BriaCell Therapeutics
BCTX----
BriaCell Therapeutics (BCTX)
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead can...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
BriaCell Therapeutics Analyst Rating
View MoreForecast & Rating
Oct 29, 2025Price forecast
$150.004089.94%
Forecast & RatingStrong buy
1analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 10:28 AM
BriaCell publishes investor presentation on Bria-IMT immunotherapy program for metastatic breast cancer
- Simplywall · Jul 16 at 12:08 PM
Is CRA International (CRAI) Quietly Redefining Its Oncology Consulting Edge With The Bria-IMT Mandate?
- PUBT · Jul 16 at 06:31 AM
BriaCell opens first Canadian Phase 3 trial site at Sunnybrook’s Odette Cancer Centre in Toronto
- Baystreet · Jul 15 at 09:20 AM
Stocks in Play: BriaCell Therapeutics Corp.
- PUBT · Jul 15 at 06:30 AM
BriaCell signs manufacturing deal with FUJIFILM Biotechnologies for Bria-IMT Phase 3 supply
- TradingView · Jun 26 at 03:13 PM
BriaCell subsidiary BriaPro reports $1.32M assets, $299,950 cash after sCD80 license acquisition
